Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.57 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 7/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.39 |
| ▸ | HTR3B | O95264 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3539497 | 0.82 | THRB (0.52) | HTR2CTHRBFAAHEPHX2CNR2 | |
| SCHEMBL4971542 | 0.80 | FAAH (0.61) | TLR7THRBFAAHCNR2IRAK4 | |
| SCHEMBL3535569 | 0.80 | THRB (0.51) | THRBFAAHEPHX2CNR2HTR3E | |
| SCHEMBL3536770 | 0.80 | TLR7 (0.57) | TLR7PANK3HTR2CFAAHHTT | |
| SCHEMBL3539520 | 0.76 | HTR2C (0.64) | TLR7PANK3HTR2CNPC1RAB9A | |
| SCHEMBL4982772 | 0.76 | FAAH (0.51) | THRBFAAHEPHX2CNR2NPC1 | |
| SCHEMBL13548746 | 0.75 | TLR7 (0.52) | TLR7PANK3HTR2C | |
| SCHEMBL3538271 | 0.74 | HTR2C (0.64) | TLR7PANK3HTR2CNPC1RAB9A | |
| SCHEMBL5662962 | 0.74 | TDP1 (0.51) | TLR7PANK3HTR2CEPHX2RAB9A | |
| SCHEMBL13548761 | 0.73 | TLR7 (0.52) | TLR7PANK3HTR2CRAB9AHTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979335-A2 | THIAZOLES AS 11 BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-15 | — | — | EP | claimed |
| WO-2007082808-A2 | THIAZOLES AS 11 BETA-HSD1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-26 | — | — | WO | claimed |
| US-7645773-B2 | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645773-B2 | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| EP-1979335-A2 | THIAZOLES AS 11 BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007082808-A2 | THIAZOLES AS 11 BETA-HSD1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-26 | — | — | WO | disclosed |
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GILLESPIE PAUL | 2007-07-19 | — | — | US | disclosed |
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GILLESPIE PAUL | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GOT2, PC, CYP11B2 | TLR7 2132/4885PANK3 1875/4885HTR2C 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.